EGFR mutation is the most common oncogenic change found in non-small cell lung cancers (NSLC) (including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) [55], and anti-EGFR therapy is used in the treatment of NSLC [56]. This evidence concerns the gene EGFR and adenocarcinoma.